Literature DB >> 9736222

Cytokines in idiopathic thrombocytopenic purpura (ITP).

J Andersson1.   

Abstract

Most research in idiopathic thrombocytopenic purpura (ITP) has focused on characterization of the autoantibodies directed against platelet antigens resulting in enhanced platelet elimination by macrophages. This report summarizes the current knowledge of cytokine pattern found in individuals with ITP. Serum assessment has demonstrated increased levels of interleukin (IL)-2 and interferon-gamma (IFN-gamma), while IL-4 was significantly decreased. In addition, thrombopoietin (TPO) has been found in normal levels while IL-11 has been reported to be elevated. These data indicate that ITP is associated with a Th1 type of T helper cytokine response, while that of type Th2 is downregulated. Initially, megakaryocytes are found at normal levels in bone-marrow aspirates, explaining the unchanged production of TPO. The increase in IL-11 may be reflected by the increased number of platelets being produced per megakaryocyte. However, there is little information on these events in immunocompetent sites such as bone marrow, spleen and lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736222     DOI: 10.1111/j.1651-2227.1998.tb01237.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  9 in total

1.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

2.  Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells.

Authors:  Baijun Fang; Ling Mai; Ning Li; Yongping Song
Journal:  Stem Cells Dev       Date:  2011-08-12       Impact factor: 3.272

3.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

4.  Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura.

Authors:  Chengshan Guo; Xiaoxia Chu; Yan Shi; Weidong He; Lizhen Li; Lin Wang; Yingxue Wang; Jun Peng; Ming Hou
Journal:  J Clin Immunol       Date:  2007-07-06       Impact factor: 8.317

5.  [Expression of IL-37 in peripheral blood of adults with primary immune thrombocytopenia].

Authors:  L Liu; K Feng; M L Wang; X H Shu; K S Zhou; H Zhou; X J Liu; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

6.  DNA methyltransferase 3B gene promoter and interleukin-1 receptor antagonist polymorphisms in childhood immune thrombocytopenia.

Authors:  Margarita Pesmatzoglou; Marilena Lourou; George N Goulielmos; Eftichia Stiakaki
Journal:  Clin Dev Immunol       Date:  2012-09-19

7.  Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports.

Authors:  Barry Bockow; Tamara Bockow Kaplan
Journal:  J Med Case Rep       Date:  2013-04-04

8.  Interleukin-1B (IL-1B-31 and IL-1B-511) and interleukin-1 receptor antagonist (IL-1Ra) gene polymorphisms in primary immune thrombocytopenia.

Authors:  Deependra Kumar Yadav; Anil Kumar Tripathi; Divya Gupta; Saurabh Shukla; Aloukick Kumar Singh; Ashutosh Kumar; Jyotsna Agarwal; K N Prasad
Journal:  Blood Res       Date:  2017-12-26

9.  The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP.

Authors:  Noriyuki Takahashi; Takayuki Saitoh; Nanami Gotoh; Yasuhiro Nitta; Lobna Alkebsi; Tetsuhiro Kasamatsu; Yusuke Minato; Akihiko Yokohama; Norifumi Tsukamoto; Hiroshi Handa; Hirokazu Murakami
Journal:  BMC Immunol       Date:  2017-05-16       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.